FDA Draft Guidance Clarifies OTC Time & Extent Applications
This article was originally published in The Rose Sheet
Executive Summary
Time & extent applications for OTC monograph eligibility should describe adverse event reporting systems in countries outside the U.S. where active ingredients have been marketed, according to an FDA draft guidance